Position in TNGX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$12,969,836
New position
Shares Held
414,902
first reported quarter
Ownership
0.246%
of shares outstanding
% of Portfolio
0.38%
of 13F equity value
Holder Rank
#66
of 247 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 100%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Longaeva Partners L.P. holds $318,796,543 across 43 Biotechnology names. TNGX ranks #9 (4.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | QURE |
uniQure N.V.
|
804,594 | $37,059,599 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
110,261 | $33,191,868 | |
| 3 | INSM |
INSMED Inc
|
201,226 | $21,454,716 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
68,792 | $16,576,808 | |
| 5 | ELVN |
Enliven Therapeutics, Inc.
|
312,560 | $15,862,420 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
30,279 | $15,040,487 | |
| 7 | BBIO |
BridgeBio Pharma, Inc.
|
187,863 | $13,992,036 | |
| 8 | CTNM |
Contineum Therapeutics, Inc.
|
812,757 | $13,321,087 |
All Filings in TNGX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $12,969,836 | 414,902 | Shares | Other | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||